Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBITDA (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of EBITDA data on record, last reported at -$19.7 million in Q4 2024.

  • For Q4 2024, EBITDA rose 14.37% year-over-year to -$19.7 million; the TTM value through Dec 2024 reached -$85.7 million, up 10.08%, while the annual FY2024 figure was -$85.7 million, 10.08% up from the prior year.
  • EBITDA reached -$19.7 million in Q4 2024 per FHTX's latest filing, down from -$18.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$13.5 million in Q3 2023 and bottomed at -$29.4 million in Q1 2023.
  • Average EBITDA over 5 years is -$23.2 million, with a median of -$23.1 million recorded in 2021.
  • Peak YoY movement for EBITDA: plummeted 64.66% in 2021, then surged 50.74% in 2023.
  • A 5-year view of EBITDA shows it stood at -$20.8 million in 2020, then tumbled by 40.22% to -$29.1 million in 2021, then grew by 3.81% to -$28.0 million in 2022, then grew by 17.74% to -$23.0 million in 2023, then rose by 14.37% to -$19.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$19.7 million in Q4 2024, -$18.4 million in Q3 2024, and -$22.8 million in Q2 2024.